The Ledger

A health system affiliate just agreed to buy one of the country’s largest private-equity-backed surgery center operators. HealthSpan Partners, a contractual affiliate and supporting organization of Bon Secours Mercy Health, will acquire Surgery Partners (NASDAQ: SGRY) for an enterprise value of about $5.7 billion, according to the companies’ joint press release filed with the SEC on Monday. Shareholders other than Bain Capital affiliates get $23.50 in cash per share. Bain, which holds about 39% of the stock per press reports, will roll its shares into equity of the buyer, stay a “significant partner,” and has signed a voting and support agreement. Surgery Partners brings more than 200 locations in 30 states and about 5,000 affiliated physicians, across ambulatory surgery centers, surgical hospitals and physician partnerships in orthopedics and spine, cardiology, gastroenterology and ophthalmology. HealthSpan says it will pay with cash on hand and new debt, with commitments secured, and expects to close in the first quarter of 2027, subject to a Surgery Partners shareholder vote and regulatory approvals. Press reports put the price at roughly a 49% premium to Friday’s close; the release does not state a premium. Who it hits: independent surgeons and health system joint venture partners inside Surgery Partners’ network, commercial insurers that negotiate with both a hospital system and a large surgery-center chain, and other private-equity-owned outpatient platforms now benchmarked against this price. So what: a nonprofit system buying a leveraged, investor-owned outpatient platform inverts the usual direction of the sector, and the regulatory review will show how enforcers treat a hospital-affiliated buyer that gains a national surgery center footprint. The release does not say which Surgery Partners joint ventures with other health systems are affected. Confidence: High on price, structure, Bain rollover and timing (company release); Med on the premium and Bain’s ownership share (press reports); Low on regulatory outcome.

Last week’s two largest healthcare take-outs were in diagnostics and lab tools, and both are still pending. Labcorp agreed October 20 to buy Myriad Genetics’ Prenatal Health testing business, which includes the Prequel, Foresight, SneakPeek and FirstGene tests, for $210 million in cash plus inventory, per the Labcorp press release. Labcorp expects about $160 million of first-year revenue and a close by early 2027. On October 21 an EQT-led bidder offered €46.50 a share in cash for the lab-tools maker QIAGEN, an enterprise value of about €10.8 billion (about $12.1 billion), a 40.3% premium to the July 8 price before takeover reports, per the bidder’s offer document filed with the SEC. The offer needs acceptance by more than half of QIAGEN’s shares and is expected to close in mid-2027. Who it hits: clinical labs, genetic testing competitors and the health systems and payers that buy their tests. So what: these are earlier deals, not new today, but with Surgery Partners they put three large healthcare transactions in the first stage of review in the same week. Confidence: High on terms (company release and filing); Low on timing of regulatory clearance.

THE DEAL SHEET

Scan covered company releases, SEC filings and trade press for October 25 and 26. No new health system bankruptcy, rating action, closure, or FTC or DOJ healthcare merger action dated in the window could be confirmed from a primary source. Earlier deals, listed for reference and not new: Labcorp and Myriad Genetics’ prenatal unit, $210 million, October 20; EQT and QIAGEN, about €10.8 billion enterprise value, October 21. Frontier scan this run: medical supplies and durable medical equipment (SC-8); only early-2026 deals surfaced and nothing fresh, so no story ran.